Cargando…

Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres

BACKGROUND: Nintedanib has been shown to slow disease progression in patients with idiopathic pulmonary fibrosis (IPF). It was approved by the National Institute for Health and Care Excellence (NICE) in January 2016 for IPF patients with a forced vital capacity (FVC) of 50–80% in the United Kingdom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Toellner, Hannah, Hughes, G., Beswick, W., Crooks, M. G., Donaldson, C., Forrest, I., Hart, S. P., Leonard, C., Major, M., Simpson, A. J., Chaudhuri, N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5670096/ https://www.ncbi.nlm.nih.gov/pubmed/29101500 http://dx.doi.org/10.1186/s40169-017-0172-3

Ejemplares similares

Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis
por: Hughes, Gareth, et al.
Publicado: (2016)

Talaromycosis in a Patient on Nintedanib for Interstitial Lung Disease
por: Madgula, Anantha Sriharsha, et al.
Publicado: (2020)

Nintedanib in children and adolescents with fibrosing interstitial lung diseases
por: Deterding, Robin, et al.
Publicado: (2023)

Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
por: Lamb, Yvette N.
Publicado: (2021)

Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases
por: Wollin, Lutz, et al.
Publicado: (2019)

Effects of nintedanib by inclusion criteria for progression of interstitial lung disease
por: Maher, Toby M., et al.
Publicado: (2022)

A Review of the Multidisciplinary Diagnosis of Interstitial Lung Diseases: A Retrospective Analysis in a Single UK Specialist Centre
por: Chaudhuri, Nazia, et al.
Publicado: (2016)

Impact of COVID-19 pandemic on prevalence of Clostridioides difficile infection in a UK tertiary centre
por: Voona, Sanjana, et al.
Publicado: (2022)

A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK
por: Rinciog, C., et al.
Publicado: (2016)

Therapeutic effect of nintedanib on acute exacerbation of interstitial lung diseases
por: Ito, Yoko, et al.
Publicado: (2019)

Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
por: Cottin, Vincent, et al.
Publicado: (2021)

Correction to: Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
por: Lamb, Yvette N.
Publicado: (2021)

A successful treatment of rheumatoid arthritis-related interstitial pneumonia with nintedanib
por: Kakuwa, Tamaki, et al.
Publicado: (2018)

Exposure–safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease
por: Schmid, Ulrike, et al.
Publicado: (2021)

Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial
por: Flaherty, Kevin R., et al.
Publicado: (2022)

Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience
por: Rivera-Ortega, Pilar, et al.
Publicado: (2018)

Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases
por: Bonella, Francesco, et al.
Publicado: (2022)

Nintedanib for progressive fibrosing interstitial lung disease: how many meet criteria in a UK district general hospital systemic sclerosis cohort?
por: Ho, Gen Nen, et al.
Publicado: (2023)

Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice
por: Fletcher, Sophie V., et al.
Publicado: (2018)

Combination Therapy with Nintedanib and Sarilumab for the Management of Rheumatoid Arthritis Related Interstitial Lung Disease
por: Vacchi, Caterina, et al.
Publicado: (2020)

Cost-Effectiveness of Nintedanib for Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
por: Westerink, Lotte, et al.
Publicado: (2022)

Nintedanib administration after the onset of acute exacerbation of interstitial lung disease in the real world
por: Kato, Motoyasu, et al.
Publicado: (2023)

Bullous pemphigoid associated with nintedanib
por: Hasson, Amelia M., et al.
Publicado: (2019)

Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON
por: Allanore, Yannick, et al.
Publicado: (2022)

Spontaneous pneumothorax during nintedanib therapy in patients with systemic sclerosis‐associated interstitial lung disease
por: Sumi, Toshiyuki, et al.
Publicado: (2021)

Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression
por: Khanna, Dinesh, et al.
Publicado: (2023)

Efficacy and Tolerability of Nintedanib in Idiopathic-Inflammatory-Myopathy-Related Interstitial Lung Disease: A Pilot Study
por: Liang, Junyu, et al.
Publicado: (2021)

Systemic Sclerosis Associated Interstitial Lung Disease and Nintedanib: A Rare Disease and a Promising Drug
por: Kafle, Sunam, et al.
Publicado: (2021)

Suppression of epithelial abnormalities by nintedanib in induced-rheumatoid arthritis-associated interstitial lung disease mouse model
por: Miura, Yoko, et al.
Publicado: (2021)

Effect of nintedanib on acute exacerbations of fibrosing interstitial lung diseases: a national database study in Japan
por: Urushiyama, Hirokazu, et al.
Publicado: (2022)

Efficacy and Safety of Nintedanib in Patients with Interstitial Lung Disease with or without Systemic Sclerosis: A Meta-Analysis
por: Lee, Young Ho, et al.
Publicado: (2023)

Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial
por: Seibold, James R, et al.
Publicado: (2020)

Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease
por: Deterding, Robin, et al.
Publicado: (2021)

The burden of progressive fibrotic interstitial lung disease across the UK
por: Simpson, Thomas, et al.
Publicado: (2021)

Nintedanib and intensive immunosuppressive therapy to treat rapidly progressive interstitial lung disease presenting anti-ARS antibodies
por: Yanagihara, Toyoshi, et al.
Publicado: (2020)

Three cases of sequential treatment with nintedanib following pulsed-dose corticosteroids for acute exacerbation of interstitial lung diseases
por: Nakashima, Kazuki, et al.
Publicado: (2021)

The safety of nintedanib for the treatment of interstitial lung disease: A systematic review and meta-analysis of randomized controlled trials
por: Chen, Chao-Hsien, et al.
Publicado: (2021)

Nintedanib induces gene expression changes in the lung of induced-rheumatoid arthritis–associated interstitial lung disease mice
por: Mikami, Shintaro, et al.
Publicado: (2022)

Nintedanib in Patients With Autoimmune Disease–Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial
por: Matteson, Eric L., et al.
Publicado: (2022)

Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review
por: Amati, Francesco, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kp9ik1o0915rn7df7o5lvemb66